title: Effect of cardiac rehabilitation and statin treatment on anti-HSP antibody titers in patients with coronary artery disease after percutaneous coronary intervention.
abstract: Accumulating evidence suggests that higher antibody titers to heat shock proteins (HSPs) are associated with the development and severity of atherosclerosis. The aim of this study was to evaluate the impact of cardiac rehabilitation therapy (CRT) or stain treatment (STT) or a combination of both (COM) on anti-HSP antibodies in patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI). Clinical evaluation of subjects was performed both at the commencement and completion of the 14 weeks of treatment. CRT consisted of a supervised 6 weeks of exercise following hospital discharge and 8 weeks of home stay exercise. Patients assigned to statin therapy were treated with 80 mg per day of fluvastatin. Blood samples from 39 patients were analyzed for antibodies to HSP60 and HSP70 by ELISA. Biochemical parameters, including lipids, high-sensitivity C reactive protein (hsCRP), and interleukin-6 (IL-6), were also analyzed. We found that CRT and COM reduced antibody titers to HSP60 and HSP70 in CAD patients (by 3.79 and 10.00% of anti-HSP60, and by 5.74 and 3.45% of anti-HSP70, respectively) but statin treatment reduced only antibody titers to HSP70 (by 3.83%). There was a significant correlation between antibody titers to HSP60 versus HSP70. Considering the fact that antibody titers to HSPs are associated with the autoimmune process in CAD, CRT and COM have greater effects on reduction in autoimmune reaction after PCI than statin treatment. This reduction was accompanied by greater improvements in blood biochemical variables, such as lipids, hsCRP, and IL-6 after CRT and COM.
authors.affiliation: Department of Physiology, College of Medicine, Soonchunhyang University, Ssangyong-dong, Cheonan, Korea.
authors.forename: Young-Oh
authors.initials: YO
authors.lastname: Shin
authors.forename: Jun-Sang
authors.initials: JS
authors.lastname: Bae
authors.forename: Jeong-Beom
authors.initials: JB
authors.lastname: Lee
authors.forename: Jung-Kyu
authors.initials: JK
authors.lastname: Kim
authors.forename: Young-Joo
authors.initials: YJ
authors.lastname: Kim
authors.forename: Chul
authors.initials: C
authors.lastname: Kim
authors.forename: Jae-Ki
authors.initials: JK
authors.lastname: Ahn
authors.forename: In-Keol
authors.initials: IK
authors.lastname: Bang
authors.forename: Byoung-Kwon
authors.initials: BK
authors.lastname: Lee
authors.forename: Timothy
authors.initials: T
authors.lastname: Othman
authors.forename: Young-Ki
authors.initials: YK
authors.lastname: Min
authors.forename: Hun-Mo
authors.initials: HM
authors.lastname: Yang
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D001323:Autoantibodies / Q000097:blood*; D018834:Chaperonin 60 / Q000276:immunology; D003327:Coronary Disease / Q000276:immunology* / Q000534:rehabilitation / Q000628:therapy*; D005081:Exercise Therapy; D005260:Female; D018840:HSP70 Heat-Shock Proteins / Q000276:immunology; D006360:Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D001323:Autoantibodies; D018834:Chaperonin 60; D018840:HSP70 Heat-Shock Proteins; D006360:Heat-Shock Proteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids